title: Editorial commentary: Bloodstream infection caused by extended-spectrum β-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?
authors.affiliation: Medicine Research Services, Louis Stokes Cleveland Department of Vetarans Affairs Medical Center Department of Medicine.
authors.forename: Federico
authors.initials: F
authors.lastname: Perez
authors.affiliation: Medicine Research Services, Louis Stokes Cleveland Department of Vetarans Affairs Medical Center Department of Medicine Department of Pharmacology Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Bonomo
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology*; D015780:Carbapenems / Q000627:therapeutic use*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010397:Penicillanic Acid / Q000031:analogs & derivatives*; D065093:beta-Lactamase Inhibitors / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid
keywords: bloodstream infection; carbapenems; extended-spectrum β-lactamases; β-lactam/β-lactamase inhibitor combinations